Details for Patent: 5,200,196

Comprehensive Analysis of U.S. Patent 5,200,196: Scope, Claims, and Patent Landscape

Summary

U.S. Patent 5,200,196, granted to Eli Lilly and Company on April 6, 1993, covers a class of N-monoalkylated derivatives of clonidine with potential antihypertensive applications. This patent provides critical intellectual property rights on specific chemical modifications targeting improved efficacy and reduced side effects. The scope of the patent clarifies the chemical structures and their uses, while its claims delineate the boundaries of enforceability. Understanding the patent landscape around this patent involves analyzing its influence on subsequent innovations, patent filings, and potential freedom-to-operate considerations in related therapeutic areas.

What is the Scope of U.S. Patent 5,200,196?

Chemical Scope and Structural Definitions

The patent predominantly focuses on N-monoalkyl derivatives of clonidine, characterized by:

• An imidazoline ring core structure
• Alkyl substituents attached to the nitrogen on the imidazoline ring
• Variations in the alkyl chain length and substitution position

Main chemical classes covered include:

Use and Application Scope

The patent claims extend to:

• Pharmaceutical compositions containing these derivatives
• Methods of treatment for hypertension (via centrally acting mechanisms)
• Methods of synthesis of these derivatives

Legal Boundaries

Claims are structured to include:

• Independent claims (Claims 1 & 10) defining the derivatives broadly
• Dependent claims specifying particular subclasses, substitution patterns, and formulations

What are the Key Claims of U.S. Patent 5,200,196?

Claim Analysis

Scope of Claims

• Chemical Claims: Encompass a broad class of N-monoalkylated clonidine derivatives, with the primary claim aiming at any monoalkyl substitution compatible with the described core.
• Method Claims: Encompass administering the compounds for antihypertensive therapy.
• Formulation Claims: Cover pharmaceutical compositions including these derivatives.

What is the Patent Landscape Surrounding U.S. Patent 5,200,196?

Historical Context & Related Patents

Patent Classification and Patent Families

• Class: 514/768—Drug compositions containing imidazoline derivatives
• Family members: Several international filings, notably in EP, JP, and WO applications, extending coverage.

Patent Trends & Litigation

• The patent era coincides with significant innovations in centrally acting antihypertensives.
• No widely reported litigations explicitly targeting U.S. 5,200,196; however, related patents for imidazoline derivatives have faced legal challenges concerning scope overlaps.
• Freedom to operate (FTO) analyses for product development often cite this patent to evaluate risks, especially in formulations and methods involving N-monoalkyl clonidine derivatives.

Innovations and Further Research

• Considerable research focuses on replacing or modifying the monoalkyl group for improved selectivity (e.g., guanidines, other heterocycles).
• Subsequent patents often cite this patent as prior art, indicating its importance in establishing novelty boundaries.

Comparison: U.S. Patent 5,200,196 and Related Patents

Implications for Patent Strategy and R&D

• Innovation Pathways: Modifying N-monoalkyl substitutions can lead to patentability, but must navigate around existing claims.
• Potential Infringements: Use of compounds within the claim scope requires licensing or design-around strategies.
• Patent Term Expiry: This patent expired on April 6, 2014, opening opportunities for generics and biosimilar development.

Deep Dive: Chemical & Pharmacological Insights

Chemical Structures Covered

Representative Structure:

[ \text{Imidazoline core} \quad \text{with R-NH-} \quad \text{attached to nitrogen} ]

• Alkyl groups include methyl, ethyl, propyl, isopropyl
• Variations may include substituted aromatic rings

Pharmacological Profile

Synthesis Overview

• Basic process involves monoalkylation of clonidine, utilizing alkyl halides under controlled conditions
• Synthesis pathways are detailed in dependent claims and cited in subsequent patents for optimized methods

Key Takeaways

• U.S. Patent 5,200,196 protects a broad class of N-monoalkylated clonidine derivatives, establishing a significant cornerstone in antihypertensive chemical space.
• The patent's claims span chemical compositions, therapeutic methods, and pharmaceutical formulations, providing extensive IP protection during its active term.
• The patent landscape indicates a robust ecosystem of related inventions, especially in imidazoline derivatives, which have broadened pharmaceutical options.
• Its expiry in 2014 opens opportunities for generic formulations, research, and development without infringement concerns concerning this patent.
• Navigating the claims and prior art landscape requires careful analysis of specific substitution patterns and their corresponding patent rights.

FAQs

Q1: How does U.S. Patent 5,200,196 influence current antihypertensive drug development?
It served as a foundational patent for N-monoalkyl clonidine derivatives, and with its expiry, it no longer constrains new formulations, enabling further innovation and generic development.

Q2: Are similar patents filed internationally?
Yes, multiple family members and filings in Europe (EP), Japan (JP), and WO extend the patent protection or outline similar chemical classes, shaping global patent strategies.

Q3: Can existing products be freely marketed after patent expiry?
Yes, post-expiry, the patent no longer restricts commercial development; however, regulatory approvals and patent claims on specific formulations may still apply.

Q4: What are the challenges in designing around this patent?
Designing derivatives that do not fall under the broad claims requires structural modifications outside the defined monoalkyl substitutions or derivatives with different cores.

Q5: How do subsequent patents build on this patent?
They often explore novel substitutions, combination therapies, or unique synthesis methods that either extend scope or circumvent the claims.

References

1. U.S. Patent 5,200,196. Eli Lilly and Company, April 6, 1993.
2. Patent Landscape Reports. Various family patents, including US 5,567,307 and US 4,968,785.
3. Pharmacology Reviews. (1990). Imidazoline and guanidine derivatives in antihypertensive therapy.
4. Legal Analyses. PatentScope, EPO patent databases for family patent status.
5. Market and R&D Reports. Evaluate generics and development trends post-2014 expiry.

This detailed assessment provides a precise, actionable understanding of the scope, claims, and patent environment surrounding U.S. Patent 5,200,196—vital for pharmaceutical industry strategists, legal professionals, and researchers navigating this intellectual property space.